이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Schrödinger 배당금

배당금 기준 확인 0/6

Schrödinger 배당금을 지급한 기록이 없습니다.

주요 정보

n/a

배당 수익률

n/a

지급 비율

업계 평균 수익률	1.1%
다음 배당금 지급일	n/a
전 배당일	n/a
주당 배당금	n/a
주당 순이익	-US$1.97
3년 후 배당 수익률 예측	0%

최근 배당금 업데이트

업데이트 없음

Recent updates

We Think The Compensation For Schrödinger, Inc.'s (NASDAQ:SDGR) CEO Looks About Right

Jun 12

Schrödinger: More Pharmaceutical Than Software

May 07

Schrödinger, Inc. (NASDAQ:SDGR) Not Flying Under The Radar

May 02

Schrödinger, Inc. (NASDAQ:SDGR) Analysts Just Cut Their EPS Forecasts Substantially

Mar 01

Is There An Opportunity With Schrödinger, Inc.'s (NASDAQ:SDGR) 49% Undervaluation?

Jul 01

Schrödinger: Q2 Earnings Supports Growth Narrative

Aug 26

Schrödinger appoints Dr. Geoffrey Porges as finance chief

Aug 18

Sizing Up Schrodinger

Jun 06

Schrödinger: Holding The Keys To Discovery

Mar 26

Schrodinger: A Long-Term Hold For Biotech Investors With Upside Potential Too

Mar 15

Schrödinger: Conviction Remains High, Q4 Report And Guidance Will Be Critical

Jan 06

After Its Stock Price Doubled Last Year, Why Schrödinger Is Slumping Now

Nov 24

We're Interested To See How Schrödinger (NASDAQ:SDGR) Uses Its Cash Hoard To Grow

Nov 12

An Intrinsic Calculation For Schrödinger, Inc. (NASDAQ:SDGR) Suggests It's 38% Undervalued

Oct 05

Schrodinger: An Investment In Drug Discovery In Addition To Software Sales

Sep 20

결제의 안정성과 성장

배당금 데이터 가져오기

안정적인 배당: 과거에 SDGR 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.

배당금 증가: SDGR 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.

시장 대비 배당 수익률

Schrödinger 시장 대비 배당 수익률

SDGR 배당 수익률은 시장과 어떻게 비교되나요?
세그먼트	배당 수익률
회사 (SDGR)	n/a
시장 하위 25% (US)	1.5%
시장 상위 25% (US)	4.7%
업계 평균 (Healthcare Services)	1.1%
3년 후 애널리스트 예측 (SDGR)	0%

주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 SDGR 의 배당 수익률을 평가할 수 없습니다.

고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 SDGR 의 배당 수익률을 평가할 수 없습니다.

주주에 대한 수익 배당금

수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 SDGR 의 지급 비율을 계산하기에는 데이터가 부족합니다.

주주에 대한 현금 배당금

현금 흐름 범위: SDGR 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.

Schrödinger 배당금

배당금 기준 확인 0/6

주요 정보

최근 배당금 업데이트

Recent updates

We Think The Compensation For Schrödinger, Inc.'s (NASDAQ:SDGR) CEO Looks About Right

Schrödinger: More Pharmaceutical Than Software

Schrödinger, Inc. Provides Earnings Guidance for the Second Quarter of 2024 and Fiscal Year Ending December 31, 2024

New minor risk - Profitability

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Schrödinger, Inc. (NASDAQ:SDGR) Not Flying Under The Radar

Schrödinger, Inc., Annual General Meeting, Jun 18, 2024

Schrödinger, Inc. to Report Q1, 2024 Results on May 01, 2024

Consensus revenue estimates fall by 18%

New minor risk - Share price stability

Schrödinger, Inc. (NASDAQ:SDGR) Analysts Just Cut Their EPS Forecasts Substantially

Schrodinger: Conservative Guidance Sets The Stock Up For A Solid 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Is Now An Opportune Moment To Examine Schrödinger, Inc. (NASDAQ:SDGR)?

Investor sentiment improves as stock rises 18%

The Price Is Right For Schrödinger, Inc. (NASDAQ:SDGR) Even After Diving 26%

Price target decreased by 7.5% to US$43.67

Schrödinger, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Schrödinger, Inc.'s (NASDAQ:SDGR) P/S Still Appears To Be Reasonable

Investor sentiment improves as stock rises 30%

Price target decreased by 14% to US$48.67

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased by 14% to US$48.67

Price target decreased by 7.0% to US$54.44

Schrödinger, Inc. to Report Q3, 2023 Results on Nov 01, 2023

Investor sentiment deteriorates as stock falls 16%

Schrödinger, New York City College of Technology, and LaGuardia Community College Receives $1 Million Grant from the National Science Foundation to Increase Access to Computational Molecular Modeling Education

Is Now An Opportune Moment To Examine Schrödinger, Inc. (NASDAQ:SDGR)?

Executive VP & CTO notifies of intention to sell stock

Investor sentiment deteriorates as stock falls 23%

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased by 8.4% to US$58.56

Chief Legal & People Officer notifies of intention to sell stock

Is There An Opportunity With Schrödinger, Inc.'s (NASDAQ:SDGR) 49% Undervaluation?

Price target increased by 7.3% to US$55.56

New major risk - Revenue and earnings growth

Independent Director exercised options and sold US$349k worth of stock

Consensus EPS estimates increase from loss to US$0.394 profit

Schrödinger, Inc. Provides Earnings Guidance for the Second Quarter and Full Year Ending December 31, 2023

First quarter 2023 earnings: EPS exceeds analyst expectations

Insufficient new directors

Consensus EPS estimates upgraded to US$0.31 loss

Consensus EPS estimates fall by 21%

Price target decreased by 7.7% to US$51.38

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Executive VP exercised options and sold US$606k worth of stock

Schrödinger, Inc. to Report Q4, 2022 Results on Feb 28, 2023

CEO, President & Director exercised options and sold US$1.1m worth of stock

Forecast to breakeven in 2025

Schrödinger Presents New Preclinical Data Supporting Advancement of CDC7 Inhibitor Development Candidate, SGR-2921

Price target decreased to US$61.00

Price target decreased to US$61.00

Third quarter 2022 earnings released: US$0.56 loss per share (vs US$0.49 loss in 3Q 2021)

Schrödinger, Inc. Provides Earnings Guidance for the Fiscal Year 2022

Schrödinger, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Schrödinger, Inc. Appoints Geoffrey Porges as CFO

Schrödinger: Q2 Earnings Supports Growth Narrative

Schrödinger, Inc. Announces CFO Changes

Schrödinger appoints Dr. Geoffrey Porges as finance chief

No longer forecast to breakeven

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Schrödinger, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Schrödinger, Inc. Announces FDA Clearance of Investigational New Drug Application for SGR-1505, a MALT1 Inhibitor

Sizing Up Schrodinger

Schrödinger, Inc. Appoints of Arun Oberoi to Board of Directors

No longer forecast to breakeven

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Schrödinger, Inc. Provides Revenue Guidance for the Fiscal Year Ending December 31, 2022

Forecast breakeven date pushed back to 2024

Schrödinger, Inc. to Report Q1, 2022 Results on May 04, 2022

Schrödinger, Inc. Reports New Preclinical Data Supporting Advancement of Its Wee1 Inhibitor Program At American Association of Cancer Research 2022 Annual Meeting

Schrödinger: Holding The Keys To Discovery

Schrodinger: A Long-Term Hold For Biotech Investors With Upside Potential Too

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates fall by 56%